ReviewInternational journal of cancer2025
CD86, the double agent: Significance of CD86 expression in B-cell malignancies.
Review in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- sMICA/sMICB and Immune Checkpoint in Endometriosis: Toward a Minimally Invasive Diagnostic Model Based on Machine Learning.Biomedicines · 2026Article
- Association of Galectin-9 Soluble Immune Checkpoint with Clinical Prognostic Markers in Patients with Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2025Article
- CD86, the double agent: Significance of CD86 expression in B-cell malignancies.International journal of cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bypassing the anti-tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA-4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an important role in immune processes. CD86 is widely expressed in hematological tumors, mainly of B-cell origin, and only a few studies are available about its role in the pathogenesis. This study discusses the importance of CD86 expression in hematological malignancies. Does its presence help or hinder the development and survival of tumor cells? The answer to this question will facilitate a more profound comprehension of the biology of hematological malignancies and the development of new therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.